ANDREW GERGELY: Open Payments
NPI 1336144831 · DUNKIRK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 71 payments from 14 companies in 2025. Trend: 2023 $1,600 · 2024 $1,692 · 2025 $1,143
Food & beverage: $1,143
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 19 | $215 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $203 |
| ABBVIE INC. | 15 | $171 |
| Vanda Pharmaceuticals Inc. | 4 | $127 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Alkermes, Inc. | 4 | $73 |
| Tris Pharma Inc | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Lundbeck LLC | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $31 |
Products named: Jornay PM, CAPLYTA, VRAYLAR, REXULTI, ARISTADA, HETLIOZ, FANAPT, Dyanavel XR.
Industry payments across MD — which companies pay providers there.
